Publication date: Dec 31, 2024
The long-term complications of coronavirus disease 2019 (COVID-19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection. Only participants confirmed by real-time reverse transcription-polymerase chain reaction tests to have COVID-19 were enrolled in the COVID-19 group. The matched cohort without COVID-19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID-19 patients (9. 58% of the total population of South Korea) and an equivalent number of matched non-infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID-19 cohort, even after multivariable adjustment for potential confounders. COVID-19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.
| Concepts | Keywords |
|---|---|
| Alopecia | alopecia areata |
| Coronavirus | COVID‐19 |
| Dermatol | herpes zoster |
| Global | urticaria |
| Matched | vitiligo |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | chronic urticaria |
| disease | MESH | vitiligo |
| disease | MESH | alopecia areata |
| disease | MESH | herpes zoster |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | MESH | complications |
| disease | MESH | urticaria |